July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Comparison of Efficacy of Various shRNAs Targeting Human RHO mRNA in Cultured Cells as Model Therapeutics for Autosomal Dominant Retinitis Pigmentosa
Author Affiliations & Notes
  • Zahra Fayazi
    Research Service , VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology, University at Buffalo-SUNY, Buffalo, New York, United States
  • Jason Myers
    Research Service , VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology, University at Buffalo-SUNY, Buffalo, New York, United States
  • Mark Christian Butler
    Research Service , VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology, University at Buffalo-SUNY, Buffalo, New York, United States
  • Alexandria J Trujillo
    Research Service , VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology, University at Buffalo-SUNY, Buffalo, New York, United States
  • Jack M Sullivan
    Research Service , VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology, University at Buffalo-SUNY, Buffalo, New York, United States
  • Footnotes
    Commercial Relationships   Zahra Fayazi, None; Jason Myers, None; Mark Butler, None; Alexandria Trujillo, None; Jack Sullivan, US 8252527 (P)
  • Footnotes
    Support  NIH/NEI EY013433, VA-1I01-BX000669, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4544. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zahra Fayazi, Jason Myers, Mark Christian Butler, Alexandria J Trujillo, Jack M Sullivan; Comparison of Efficacy of Various shRNAs Targeting Human RHO mRNA in Cultured Cells as Model Therapeutics for Autosomal Dominant Retinitis Pigmentosa. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4544.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Compare efficacy and properties shRNAs designed against human rhodopsin (hRHO) mRNA in a human cell culture environment with the goal of developing a potential post-transcriptional gene silencing (PTGS) therapeutic agent for autosomal dominant retinitis pigmentosa (adRP).

Methods : The expression of full length hRHO including 5`UTR and 3`UTR (1st polyA signal) was driven by CMV promoter and shRNAs with H1 promoter in HEK293S cells. hRHO mRNA was quantified using the DDCt method relative to actin mRNA control. Alexa647-labeled anti-hRHO-1D4 antibody was used to measure rhodopsin protein in cells using Quantitative Imaging platform (QIP). Data was statistically evaluated using ANOVA and post-hoc t-tests with criterion standard of significance (p≤0.05). Accessibility in regions around the binding sites in hRHO were determined by multiparameter prediction of mRNA accessibility (mppRNA). Potential off-site targeting by each shRNA was determined by BLAST-N for the full length and “seed” nucleotides.

Results : Various shRNAs from this lab and other published sources were compared for their capacity to suppress hRHO mRNA in HEK293S cells. Computationally predicted accessibility in the different targeting regions varied among shRNAs. There were few off-targets identified in the human transcriptome for the 19 nt full shRNA elements in BLAST-N. All shRNAs exerted statistically significant knockdown of hRHO mRNA relative to scrambled or irrelevant targeting element controls. We designed and characterized shRNA-725 and shRNA-906 and compared them to published shRNA-BB1 and shRNA-Q1 (O’Reilly M. et al., 2007). ShRNA-725 suppresses hRHO mRNA (p=6.53E-10) and protein (p=2.93E-7) by over 90% compared to shRNA-scramble. ShRNA-906 showed the most hRHO mRNA transcription inhibitory effect of over 95% (p=7.14E-4) compared to other shRNAs tested.

Conclusions : We identified two highly effective shRNAs (725 and 906) in predicted accessible regions of hRHO as lead candidate PTGS therapeutic agents to further evaluate in our humanized mouse model of adRP. There remains concern that “seed” sequences at 5’ positions 2-7 in any shRNA could cause a plethora of off-target effects (Gu S et al. 2014; Jackson A et al. 2006).

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×